Authorizes manufacturers of investigational drugs or biological products that are pending approval by the United States Food and Drug Administration to make the drugs or products available to terminally ill patients under certain conditions.
- Chamber
- Senate
- Introduced
- Jan 14, 2026
- Last action
- Jan 14, 2026 — Pending Introduction.
- Session
- 2026
- Momentum
- 31 · Low